Current Medical Research and Opinion

Aims & Scope

Current Medical Research and Opinion is a MEDLINE-indexed, international journal publishing papers on new and existing drugs and therapies, Phase II-IV studies, and post-marketing investigations.

Current Medical Research and Opinion especially encourages research pertaining to equivalence, safety and efficacy/effectiveness studies.

Phase I, pharmacoeconomic, outcomes and quality of life studies may also be considered if there is clear clinical relevance.

Please note CMRO does not consider pre-clinical animal studies.

All manuscripts submitted to the journal are assessed for suitability by the Editor and then peer-reviewed in a single-blind fashion.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2.2
2024	2.40

SJR (SCImago Journal Rank)

Year	Value
2024	0.786

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	125

Journal Rank

Year	Value
2024	6949

Journal Citation Indicator

Year	Value
2024	1641

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• pain<i>DETECT</i>: a new screening questionnaire to identify neuropathic components in patients with back pain

  Citation: 1816

  Authors: Rainer, Ralf, Ulrich, Thomas R.

• Incidence, patient satisfaction, and perceptions of post-surgical pain: results from a US national survey

  Citation: 680

  Authors: Tong J., Ashraf S., Timothy E., William, Jeffrey L.

• Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

  Citation: 612

  Authors: David C., John B., Loretta L., Xuesong, Christopher L., John H., Matthew E., David G.

• Good and poor adherence: optimal cut-point for adherence measures using administrative claims data

  Citation: 488

  Authors: Sudeep, Mario A., Mark, Teresa J., Donna S., Bradley C.

• The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence oSf erectile dysfunction and related health concerns in the general population

  Citation: 482

  Authors: Raymond C., William A., Ian, Craig, Andrea, Michael

• Diclofenac: an update on its mechanism of action and safety profile

  Citation: 438

  Authors: Tong J.

• The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making

  Citation: 405

  Authors: Andrew J., Stéphane, William J., Michael E., Volker, Francesco M., Morten, Giatgen A.

• Treatment-Resistant Schizophrenia - The Role of Clozapine

  Citation: 384

  Authors: Herbert Y.

• Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus

  Citation: 382

  Authors: Kristy, Hakima, Patrick, Jinfei, Xueying, Samuel S., Lori M., Swapnil

• Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention

  Citation: 381

  Authors: Vasilios G., Athanasios A., Bodosakis R., Valasia V., Athanasios N., Elias O., Dimokritos S., Athanasios G.

---